Delivery of inhibitors to NF-кB combined with immunogene therapy using Flt3L and thymidine kinase (TK) can suppress Foxp3+ Tregs and product Th1 cytokines in the tumor microenvironment [89]. The gene discussed is FLT3LG; the disease is neoplasm.